# Therapeutic modulation of empathy: pharmacological, neurostimulation, and behavioral approaches

**Authors:** Sarfaraz K. Niazi

PMC · DOI: 10.3389/fpsyg.2026.1762816 · Frontiers in Psychology · 2026-03-04

## TL;DR

This paper reviews how empathy can be therapeutically enhanced using drugs, brain stimulation, and behavior, but notes the effects are often small and short-lived.

## Contribution

A novel synthesis framework is used to integrate evidence on empathy modulation across pharmacological, neurostimulation, and behavioral approaches.

## Key findings

- Pharmacological methods like oxytocin and MDMA show small to moderate empathy effects.
- Neurostimulation techniques have limited durability of effects.
- Behavioral interventions like mindfulness show the most sustainable results.

## Abstract

Empathy is a core neurobiological capacity that enables humans to perceive, understand, and respond to others’ experiences, yet its deliberate modulation as a therapeutic target is still in its early stages of scientific development. This manuscript presents a hybrid narrative–scoping review synthesizing evidence across pharmacological, neurostimulation, and behavioral approaches aimed at enhancing or restoring empathic functioning. A structured literature search covering 2014–2025 was conducted across PubMed, PsycINFO, Web of Science, and Scopus, with emphasis on post-2020 research. Evidence was organized using an author-defined tiered synthesis framework, intended to support integrative interpretation rather than formal evidence grading. Across modalities, empathy can be modulated, but observed effect sizes are typically small to moderate, heterogeneous, and frequently transient. Pharmacological approaches such as intranasal oxytocin demonstrate modest, context-dependent effects (d = 0.24, 95% CI: 0.02–0.46), while MDMA-assisted therapy yields larger but highly context-restricted benefits (d ≈ 0.91) in trauma-focused psychotherapy and faces unresolved regulatory barriers. Neurostimulation techniques, including transcranial magnetic stimulation (d ≈ 0.18–0.20), provide causal insights into empathy-related circuits but show limited durability of behavioral effects. Behavioral interventions—particularly mindfulness-based programs (d = 0.37, 95% CI: 0.16–0.58 for programs >24 h) and compassion-focused programs—exhibit the greatest scalability and sustainability. Overall, empathy represents a scientifically promising yet clinically constrained therapeutic target. Reliable translation will require larger trials, standardized and ecologically valid outcome measures, and careful integration of neurobiological and psychosocial frameworks.

## Linked entities

- **Chemicals:** oxytocin (PubChem CID 439302), MDMA (PubChem CID 1615)

## Full-text entities

- **Diseases:** trauma (MESH:D014947)
- **Chemicals:** oxytocin (MESH:D010121), MDMA (MESH:D018817)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12995753/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12995753/full.md

## References

105 references — full list in the complete paper: https://tomesphere.com/paper/PMC12995753/full.md

---
Source: https://tomesphere.com/paper/PMC12995753